Alternatively, TCR therapy could be combined with additives that protect both T and NK cells from tumour mediated immunosuppression such as immune checkpoint inhibitors (e.g., anti-PD-1 antibodies) or cytokines (e.g., IL-15). This evidence concerns the gene PDCD1 and neoplasm.